CN107714713B - 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 - Google Patents
台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 Download PDFInfo
- Publication number
- CN107714713B CN107714713B CN201711009061.4A CN201711009061A CN107714713B CN 107714713 B CN107714713 B CN 107714713B CN 201711009061 A CN201711009061 A CN 201711009061A CN 107714713 B CN107714713 B CN 107714713B
- Authority
- CN
- China
- Prior art keywords
- tiacumicin
- dengue virus
- derivative
- application
- virus infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930187202 Tiacumicin Natural products 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 206010012310 Dengue fever Diseases 0.000 title abstract description 7
- 208000025729 dengue disease Diseases 0.000 title abstract description 7
- 208000024891 symptom Diseases 0.000 title abstract description 6
- 201000010099 disease Diseases 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 5
- 241000725619 Dengue virus Species 0.000 claims abstract description 13
- 101800000508 Non-structural protein 5 Proteins 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 208000037384 Clostridium Infections Diseases 0.000 abstract description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 abstract description 2
- 206010054236 Clostridium difficile infection Diseases 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 108700027092 dengue virus NS5 Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
antiviral EC<sub>50</sub>(μM) | CC<sub>50</sub>(μM) | |
DENV2(NGC) | A549 | |
化合物1 | 1.01±0.62 | 15.29±0.86 |
化合物2 | 2.95±0.62 | 40.23±2.40 |
KD(μM) | |
化合物1 | 6.59 |
化合物2 | 9.05 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711009061.4A CN107714713B (zh) | 2017-10-25 | 2017-10-25 | 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711009061.4A CN107714713B (zh) | 2017-10-25 | 2017-10-25 | 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107714713A CN107714713A (zh) | 2018-02-23 |
CN107714713B true CN107714713B (zh) | 2020-05-26 |
Family
ID=61212736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711009061.4A Active CN107714713B (zh) | 2017-10-25 | 2017-10-25 | 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107714713B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101340919A (zh) * | 2005-10-21 | 2009-01-07 | 奥普蒂姆药物公司 | 治疗艰难梭菌相关的腹泻的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016205009A1 (en) * | 2015-06-19 | 2016-12-22 | The Regents Of The University Of California | Treating infection by a platelet-targeting microbe using nanoparticles |
-
2017
- 2017-10-25 CN CN201711009061.4A patent/CN107714713B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101340919A (zh) * | 2005-10-21 | 2009-01-07 | 奥普蒂姆药物公司 | 治疗艰难梭菌相关的腹泻的方法 |
Non-Patent Citations (2)
Title |
---|
Chang Ching-Yun等.表现登革热二型病毒NS2,NS4基因及探讨四环霉素衍生物对登革热病毒的抑制作用.《National Chiao Tung University Institutional Repositoryhttps://ir.nctu.edu.tw/handle/11536/42711》.2008, * |
刘强强 等.登革病毒非结构蛋白NS5研究进展.《中国病毒病杂志》.2016,第6卷(第4期),第317-321页. * |
Also Published As
Publication number | Publication date |
---|---|
CN107714713A (zh) | 2018-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahmoud et al. | Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? | |
Lee et al. | Andrographolide exerts anti‐hepatitis C virus activity by up‐regulating haeme oxygenase‐1 via the p38 MAPK/N rf2 pathway in human hepatoma cells | |
Jheng et al. | ER stress, autophagy, and RNA viruses | |
CN111557939B (zh) | 法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用 | |
CN111265532A (zh) | 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用 | |
Guo et al. | A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus | |
CN113289018B (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
Ho et al. | Palmatine inhibits Zika virus infection by disrupting virus binding, entry, and stability | |
CN111402968B (zh) | 基于分子模拟发现山柰酚在covid-19病毒中的新用途 | |
Xu et al. | Drug repurposing approach to combating coronavirus: Potential drugs and drug targets | |
CN111743899B (zh) | 硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用 | |
Fang et al. | Antiviral peptides targeting the helicase activity of enterovirus nonstructural protein 2C | |
Ho et al. | In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71 | |
Li et al. | Heme Oxygenase-1 inhibits spring viremia of carp virus replication through carbon monoxide mediated cyclic GMP/Protein kinase G signaling pathway | |
Diarimalala et al. | Recent advances of enterovirus 71 3 C pro targeting Inhibitors | |
CN113813258B (zh) | 抗rna病毒药物及其应用 | |
CN107970253B (zh) | 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用 | |
US8778876B2 (en) | Small-molecule inhibitors of Dengue and West Nile virus proteases | |
CN107929300B (zh) | 非达霉素在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 | |
CN106880630B (zh) | Retro-2cycl及相关衍生物的用途 | |
CN107714713B (zh) | 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 | |
CN107737133B (zh) | 非达霉素在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用 | |
Moshiri et al. | A targeted computational screen of the SWEETLEAD database reveals FDA-approved compounds with anti-dengue viral activity | |
CN107468682B (zh) | 芒果苷在制备抗病毒药物中的应用 | |
CN112294823B (zh) | 三尖杉酯碱或其类似物的应用与所制得的制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Changsheng Inventor after: Li Mengfeng Inventor after: Zhang Haibo Inventor after: Zhu Yiguang Inventor after: Zhang Guangtao Inventor after: Yuan Jie Inventor after: Zhu Xun Inventor after: Yu Jianchen Inventor before: Li Mengfeng Inventor before: Yuan Jie Inventor before: Zhu Xun Inventor before: Yu Jianchen Inventor before: Zhang Haibo Inventor before: Zhu Yiguang Inventor before: Zhang Guangtao |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |